TY - JOUR
T1 - Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing
AU - Roy-Chowdhuri, Sinchita
AU - De Melo Gagliato, Debora
AU - Routbort, Mark J.
AU - Patel, Keyur P.
AU - Singh, Rajesh R.
AU - Broaddus, Russell
AU - Lazar, Alexander J.
AU - Sahin, Aysegul
AU - Alvarez, Ricardo H.
AU - Moulder, Stacy
AU - Wheler, Jennifer J.
AU - Janku, Filip
AU - Gonzalez-Angulo, Ana M.
AU - Chavez-MacGregor, Mariana
AU - Valero, Vicente
AU - Ueno, Naoto T.
AU - Mills, Gordon
AU - Mendelsohn, John
AU - Yao, Hui
AU - Aldape, Kenneth
AU - Luthra, Rajyalakshmi
AU - Meric-Bernstam, Funda
N1 - Publisher Copyright:
© American Society for Clinical Pathology.
PY - 2015/11
Y1 - 2015/11
N2 - Objectives: The advent of next-generation sequencing (NGS) platforms in the realm of clinical molecular diagnostics provides multigene mutational profiling through massively parallel sequencing. Methods: We analyzed 415 breast carcinoma samples from 354 patients using NGS in known hotspots of 46 commonly known cancer-causing genes. Results: A total of 281 somatic nonsynonymous mutations were detected in 62.1% of patients. TP53 was most frequently mutated (38.8%), followed by PIK3CA (31.7%), AKT1 (6%), and ATM (3.9%), with other mutations detected at a lower frequency. When stratified into clinically relevant therapeutic groups (estrogen receptor [ER]/progesterone receptor [PR]+ human epidermal growth factor receptor 2 [HER2]-, ER/PR+HER2+, ER/PR-HER2+, ER/PR/HER2-), each group showed distinct mutational profiles. The ER/PR+HER2- tumors (n = 132) showed the highest frequency of PIK3CA mutations (38%), while the triple-negative tumors (n = 64) had a significantly higher number of TP53 mutations (62%). Of the 61 patients tested for both primary and metastatic tumors, concordant results were seen in 47 (77%) patients, while 13 patients showed additional mutations in the metastasis. Conclusions: Our results indicate that breast cancers may harbor potentially actionable mutations for targeted therapeutics. Therefore, NGS-based mutational profiling can provide useful information that can guide targeted cancer therapy.
AB - Objectives: The advent of next-generation sequencing (NGS) platforms in the realm of clinical molecular diagnostics provides multigene mutational profiling through massively parallel sequencing. Methods: We analyzed 415 breast carcinoma samples from 354 patients using NGS in known hotspots of 46 commonly known cancer-causing genes. Results: A total of 281 somatic nonsynonymous mutations were detected in 62.1% of patients. TP53 was most frequently mutated (38.8%), followed by PIK3CA (31.7%), AKT1 (6%), and ATM (3.9%), with other mutations detected at a lower frequency. When stratified into clinically relevant therapeutic groups (estrogen receptor [ER]/progesterone receptor [PR]+ human epidermal growth factor receptor 2 [HER2]-, ER/PR+HER2+, ER/PR-HER2+, ER/PR/HER2-), each group showed distinct mutational profiles. The ER/PR+HER2- tumors (n = 132) showed the highest frequency of PIK3CA mutations (38%), while the triple-negative tumors (n = 64) had a significantly higher number of TP53 mutations (62%). Of the 61 patients tested for both primary and metastatic tumors, concordant results were seen in 47 (77%) patients, while 13 patients showed additional mutations in the metastasis. Conclusions: Our results indicate that breast cancers may harbor potentially actionable mutations for targeted therapeutics. Therefore, NGS-based mutational profiling can provide useful information that can guide targeted cancer therapy.
KW - Breast carcinoma
KW - ER positive
KW - Mutational profiling
KW - Next-generation sequencing
KW - Triple negative
UR - http://www.scopus.com/inward/record.url?scp=84947969268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947969268&partnerID=8YFLogxK
U2 - 10.1309/AJCPWDEQYCYC92JQ
DO - 10.1309/AJCPWDEQYCYC92JQ
M3 - Article
C2 - 26486734
AN - SCOPUS:84947969268
SN - 0002-9173
VL - 144
SP - 713
EP - 721
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 5
ER -